Japan· JP-1190700S2068
リバスチグミン
A medicinal product containing リバスチグミン, registered in Japan by 陽進堂ホールディングス, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- リバスチグミン
- Manufacturer
- 陽進堂ホールディングス
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c030420e-9fda-4240-803d-3a07a9593d56 GET /v1/drugs/c030420e-9fda-4240-803d-3a07a9593d56?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "９ｍｇ１枚",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1190700S2068",
"category": "外用薬",
"price_yen": 91.6,
"generic_name": "リバスチグミン",
"product_name_jp": null,
"therapeutic_class": "1190",
"transitional_expiry": null
}See everything about リバスチグミン.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.